COMBAT DRUGS LTD. SHARE PRICE [LIVE]

BSE: INE643N01012   NSE: COMBDRG   SECTOR: Pharma

OPEN YOUR FREE DEMAT ACCOUNT AND START TRADING SEAMLESSLY
Already an existing customer? - Login Now!
NSE
N/A
Change:
BSE
54.40
Change:
NSE
BSE Click here to view BSE data
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Open:
High:
Low:
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
P/E:
Div yield:

Fundamental analysis

Quality
Valuation
0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Stock
Sector
Sensex
Name Mar 21 Dec 20

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in COMBAT DRUGS LTD.

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

COMBDRG News

Frequently Asked Questions

What is the Share price of COMBAT DRUGS LTD. (COMBDRG)?

COMBAT DRUGS LTD. (COMBDRG) share price as of May 27, 2022, on BSE is Rs 54.40 (BSE).

Can I buy COMBAT DRUGS LTD. (COMBDRG) shares?

Yes, You can buy COMBAT DRUGS LTD. (COMBDRG) shares by opening a Demat account with Angel One.

How do I buy COMBAT DRUGS LTD. (COMBDRG) from Angel One?

COMBAT DRUGS LTD. (COMBDRG) share can be brought through the following modes:
  1. Direct investment: You can buy COMBAT DRUGS LTD. (COMBDRG) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to COMBAT DRUGS LTD. (COMBDRG) shares.

In which sector do COMBAT DRUGS LTD. (COMBDRG) belong?

COMBAT DRUGS LTD. (COMBDRG) belongs to Pharma.

About COMBDRG

Today's live share price for COMBAT DRUGS LTD. is NSE: N/A, BSE: ₹ 54.40 with a current market capitalization of .

Incorporated as a private limited company in Sep.'86, Combat Drugs (CDL) was converted into a public limited company in Jun.'92. The company was promoted by Suchit Mohan Lal and Ajay Karan. CDL came out with a public issue of 23.23 lac equity shares at par aggregating Rs 2.32 cr in Nov.'94. The proceeds of the issue were utilised to part-finance a Rs 3.25-cr project to expand the existing manufacturing facilities for pharmaceutical formulations and to diversify into the manufacture of sterile powder injectables. CDL started commercial production in Jul.'87 on a loan-licence basis. The company acquired a full-fledged manufacturing unit located at Balanagar, Hyderabad, on lease from Fairchild Laboratories and commenced commercial production in Aug.'88. In Jul.'92 the manufacturing activities were shifted to the present leased premises at Kushaiguda, Hyderabad. In this unit various pharmaceutical formulations such as tablets, capsules and liquids are being manufactured. The product range of CDL comprises vital anti-bacterial drugs, antibiotic drugs, anti-inflammatory drugs, haematenic drugs and protein tonic. CDL has developed in-house technology for the manufacture of dispersible and sustained release formulations. The company is exploring the possibilities of exporting its products to Nigeria and West Indies. During the year 1995-96, the expansion programme undertaken by the company was successfully completed and the unit at Yellampet has become operational. During 1996-97, the company has expanded its operations to new areas. It has expanded its product range by introduction of Liquid Orals. The product "HB 2" has been well accepted in the market. The company has also filled its application for obtaining the (c)GMP and WHO GMP Certificate. During the year 1998-99, the Company initiated steps to diversify into information technology. The Company is in the process of taking over the business of M/s. Softech Institute of Information Technology & Software Development, which would function as the Infotech Division of the Company. The Company also proposes to change its name to "Combat Drugs and Softech Limited" so as to justify both the activities of Pharmaceutical Formulations and Information Technology.

Read more